Market Overview

Morgan Stanley Warns Warner Chilcott's DELZICOL 'May Not Qualify for Any Marketing Exclusivity'

Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Traders in Warner Chilcott (NASDAQ: WCRX) may be considering an earlier concerning note from Morgan Stanley following news of FDA approval for DELZICOL.

After trading to an intraday high at $14.87, shares of Warner Chilcott last traded around $14.27, up about 1.4 percent from Monday's close.

Morgan Stanley analysts said, "After perusing Delzicol(new Asacol)'s label, we believe that it may not qualify for any marketing exclusivity, implying that WCRX's time to effect conversion from Asacol may be very limited." The firm believes the major difference between the labels "is that Asacol tablets contain dibutyl phthalate as an inactive ingredient while Delzicol capsules contain dibutyl sebacate."

Morgan Stanley maintains an Underweight rating on shares of Warner Chilcott.

Latest Ratings for WCRX

DateFirmActionFromTo
Jul 2013Leerink SwannUpgradesMarket PerformOutperform
Jun 2013JefferiesDowngradesBuyHold
May 2013Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WCRX
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (WCRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters